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Overabundance of Slug protein is common in human
cancer and represents an important determinant
underlying the aggressiveness of basal-like breast
cancer (BLBC). Despite its importance, this tran-
scription factor is rarely mutated in BLBC, and the
mechanism of its deregulation in cancer remains un-
known. Here, we report that Slug undergoes acetyla-
tion-dependent protein degradation and identify the
deacetylase SIRT2 as a key mediator of this post-
translational mechanism. SIRT2 inhibition rapidly
destabilizes Slug, whereas SIRT2 overexpression
extends Slug stability. We show that SIRT2 de-
acetylates Slug protein at lysine residue K116 to
prevent Slug degradation. Interestingly, SIRT2 is
frequently amplified and highly expressed in BLBC.
Genetic depletion and pharmacological inactivation
of SIRT2 in BLBC cells reverse Slug stabilization,
cause the loss of clinically relevant pathological
features of BLBC, and inhibit tumor growth. Our re-
sults suggest that targeting SIRT2 may be a rational
strategy for diminishing Slug abundance and its
associated malignant traits in BLBC.
INTRODUCTION
Over the past decade, large-scale genomic profiling has re-
vealed the molecular landscape of breast cancers (Perou et al.,
2000; van’t Veer et al., 2002), identifying discrete subtypes as
well as underlying driver genes. For the majority of breast cancer
subtypes, tailored targeted therapies are now available and
have significantly improved patient survival (Cuzick et al., 2010;
Ignatiadis et al., 2012; Regan et al., 2011; Slamon et al.,
2001). The notable exception is one of the deadlier and more
aggressive subtypes, called basal-like breast cancer (BLBC)
and so-named for its molecular similarities to the basal mam-
mary epithelial cell differentiation program (Harris et al., 2012).1302 Cell Reports 17, 1302–1317, October 25, 2016 ª 2016 The Auth
This is an open access article under the CC BY license (http://creativeSharing an immunophenotype with triple-negative breast can-
cer, BLBC is identified clinically by the absence of estrogen
receptor, progesterone receptor, and HER2, and affects approx-
imately 20% of breast cancer patients (Fan et al., 2006; Rakha
et al., 2008). Unfortunately, analyses of somatic mutation profiles
of BLBC have not yet revealed promising targets for therapeutic
intervention (Foulkes et al., 2010; Gusterson, 2009).
Robust tumorigenic capacity, early dissemination and metas-
tasis, and frequent resistance to conventional chemotherapy
and radiotherapy regimens are central clinical features of
BLBC (Foulkes et al., 2010; Harris et al., 2012; Metzger-Filho
et al., 2012; Rakha et al., 2008). Recent studies have identified
the transcriptional repressor SNAI2/Slug as a critical determi-
nant underlying these malignant phenotypes (DiMeo et al.,
2009; Phillips and Kuperwasser, 2014; Proia et al., 2011; Sa-
manta et al., 2016; Storci et al., 2008). In cancer biology, Slug
is well known to promote tumor progression and metastasis
through the epithelial-mesenchymal transition (EMT), causing
loss of cell adhesion and polarity while conferring migratory
and invasive properties (Polyak and Weinberg, 2009; Yang and
Weinberg, 2008). In addition, studies onmammary gland biology
have outlined essential roles for Slug in orchestrating transcrip-
tional programs for stem cell self-renewal and basal mammary
epithelial cell differentiation (Cobaleda et al., 2007; Guo et al.,
2012; Nassour et al., 2012; Phillips et al., 2014). By suppressing
the luminal differentiation program while activating EMT, high
Slug expression levels bias tumor development toward stem/
basal-like phenotypes and enable the adoption of tumor-initi-
ating and invasive capabilities (DiMeo et al., 2009; Proia et al.,
2011; Samanta et al., 2016; Storci et al., 2008). Experi-
mental depletion of Slug diminishes these aggressive traits,
and SNAI2 knockout animals are resistant to mammary tumori-
genesis (Phillips et al., 2014).
Consistent with Slug playing a central role in the development
of BLBC, an overabundance of Slug protein is commonly
observed in BLBC tumors (Liu et al., 2013b; Proia et al., 2011).
However, despite its frequent overabundance, SNAI2 is rarely
mutated or amplified in BLBC. Although Slug is a shorted-lived
and rapidly degraded protein in normal tissue, we have previ-
ously observed extended Slug stability in BLBC caused byors.
commons.org/licenses/by/4.0/).
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Figure 1. A Combinatorial Proteomic and Chemical Inhibitor Approach Identifies Acetylation in the Regulation of Slug Protein Turnover
(A) (Top) MCF10A cells were treated with cycloheximide (CHX) to prevent de novo protein synthesis at indicated time intervals. Immunoblots for Slug protein and
Lamin A/C loading control levels at the indicated time intervals following CHX treatment. (Bottom) Quantification of relative Slug levels from five independent
experiments, normalized to Lamin A/C levels. The half-life of Slug protein is indicated (red line). Data shown are mean ± SEM.
(B) Pie chart and table of major functional groups associated with Slug-interacting partners as identified by SLUG coIP/MS in HEK293T cells. False recovery rates
are represented as Benjamini-Hochberg p values in the table.
(C) MCF10A cells were treated with the indicated panel of chemical inhibitors or vehicle control, and Slug protein abundance was assessed by immunoblot.
Relative levels of Slug protein were quantified and are shown below the immunoblots.
(legend continued on next page)
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decreased proteasomal degradation of Slug (Proia et al., 2011).
Proteolytic turnover of Slug, like many labile transcription fac-
tors, is regulated by post-translational modifications (PTMs).
Phosphorylation mediated by GSK3b primes Slug for ubiquitina-
tion (Kao et al., 2014; Wu et al., 2012), and several E3 ligases
(FBXL14, b-Trcp1, and CHIP) are involved in the ubiquitin-medi-
ated degradation of Slug (Kao et al., 2014; Vernon and LaBonne,
2006; Wu et al., 2005, 2012). However, GSK3b inactivation does
not strongly correlate with Slug overabundance in cancer, and
prior studies have demonstrated that Slug undergoes proteaso-
mal degradation independent of GSK3b-mediated phosphoryla-
tion (Lander et al., 2011; Vin˜as-Castells et al., 2010). Therefore,
the mechanism by which Slug escapes proteasomal degrada-
tion in BLBC remains unknown.
We reasoned that elucidating the molecular mechanism
underlying the phenomenon of extended Slug stability could
provide a new target for BLBC therapeutic intervention. Thus,
in this study, we endeavored to identify the post-translational
mechanism by which Slug protein stability is regulated in breast
epithelial cells and evaluate whether components of this mecha-
nism are altered in breast cancer. We found that Slug acetyla-
tion represents a major determinant governing its abundance,
and deacetylation of the SLUG domain by the mammalian sirtuin
SIRT2 regulates Slug stability. Notably, SIRT2 is frequently
amplified in BLBC, and experimental manipulation of SIRT2 in
BLBC cells antagonized the cancer-associated phenotypes
mediated by Slug. Together, these findings unravel an intricate
molecular interplay between SIRT2 amplification, Slug stability,
and the BLBC phenotype.
RESULTS
A Combined Proteomic and Chemical Inhibitor
Approach Identifies Acetylation in theRegulation of Slug
Protein Turnover
We have previously shown that Slug protein is abundantly
expressed yet undergoes rapid turnover in normal mammary
epithelial cells (Phillips et al., 2014; Proia et al., 2011). Indeed,
in immortalized, non-transformed MCF10A human breast
epithelial cells, Slug is rapidly degraded upon cycloheximide
(CHX) blockade of de novo protein synthesis, exhibiting a half-
life of 80 min (Figure 1A). In addition, proteasomal inhibition
byMG132 treatment completely prevented Slug protein turnover
(Figure S1B). To identify proteins that may contribute to the regu-
lation of Slug protein levels, we performed immunoprecipitation
of Slug followed by mass spectrometry (coIP/MS). This proteo-
mic approach identified 287 unique Slug-binding partners (Table
S1), several of which have been previously validated (Kao et al.,
2014; Phillips et al., 2014; Wu et al., 2012). We interrogated
this list of Slug-binding partners for commonmolecular functions(D) MCF10A cells were treated with sirtinol (25 mM) for 4 hr, and Slug protein leve
(E) MCF10A cells were treated with sirtinol (25 mM) for 4 hr, and SNAI2 transcript e
p = 0.08.
(F) MCF10A cells were pre-treated with sirtinol alone (top) or sirtinol plus the prot
prevent de novo protein synthesis at indicated time intervals. Immunoblots of Sl
(G) Quantification of relative Slug protein levels from three independent experimen
of Slug protein are plotted for CHX only (blue), CHX plus sirtinol (red), and CHX p
1304 Cell Reports 17, 1302–1317, October 25, 2016using the DAVID functional annotation tool (Figures 1B and S1A)
(https://david.ncifcrf.gov/). Consistent with the function of Slug
as a DNA-binding transcriptional co-repressor, a significant
number of binding partners were nuclear proteins. However,
proteins involved in PTM were also highly represented, and sur-
prisingly, acetylation was the most statistically significant func-
tionality associated with Slug binding partners (Figure 1B; false
discovery rate [FDR] = 3.0 3 1054).
Based on these findings, we examined whether acetylation
might affect Slug protein levels. Indeed, we observed that
small-molecule inhibitors of deacetylation, targeting class I, II,
or III HDACs (TSA, sirtinol, and HDACi), resulted in dramatic re-
ductions of Slug protein in MCF10A cells, whereas other HDAC
inhibitors such as sodium butyrate and a cullin/E3 ligase inhibitor
(MLN4924) failed to appreciably affect Slug levels (Figure 1C).
Interestingly, the most selective of these HDAC inhibitors—sirti-
nol, a selective inhibitor of sirtuin 1 and 2—led to marked Slug
depletion in a dose- and time-dependent manner (Figures S1C
and S1D). Furthermore, Slug protein depletion was not a result
of transcriptional repression (Figure 1D), as SNAI2 mRNA levels
were slightly increased following sirtinol treatment (Figure 1E).
Consistent with the post-translational nature of this regulation,
sirtinol treatment drastically accelerated Slug protein turnover
and led to substantial shortening of Slug protein half-life (Figures
1F and 1G, *p < 0.05). Moreover, the sirtinol-induced loss of Slug
protein also correlated with de-repression of EPCAM andCDH1,
two canonical Slug target genes (Figure S1E, **p < 0.01). Taken
together, these data identify acetylation as a potential regulator
of Slug protein level, and show that combined pharmacological
inhibition of the deacetylases SIRT1 and SIRT2 by sirtinol is
sufficient to reduce Slug protein half-life and activity.
Protein Deacetylase SIRT2 Regulates Slug Protein
Abundance, Stability, and Function
Mammalian sirtuins (SIRT1–7) are a class of NAD+-dependent
type III histone and protein deacetylases classically known for
their regulatory roles in cellular metabolism and aging (Guarente,
2011). Interestingly, a growing body of literature highlights a
novel function of the sirtuin family in regulating the stability of
short-lived transcriptional factors, including several cancer-
relevant substrates such as p53 and FOXO3 (Liu et al., 2013b;
Hoffmann et al., 2014). Given our finding that sirtinol substantially
reduces Slug protein abundance, we investigated whether regu-
lation of Slug protein stability requires either SIRT1 or SIRT2, or
both. To this end, we individually perturbed SIRT1 and SIRT2
expression in MCF10A cells and examined the ensuing effect
on Slug. We found that neither overexpression nor depletion of
SIRT1 resulted in a significant change in Slug protein levels or
stability (Figures S2A and S2B). In contrast, overexpressing
SIRT2 resulted in a striking increase in Slug protein abundancel was assessed by immunoblot.
xpression was assessed by qRT-PCR. Data are shown as mean ± SEM (n = 3);
easome inhibitor MG132 (bottom), and then subsequently treated with CHX to
ug and Lamin A/C protein levels are shown at the indicated time intervals.
ts performed as in (F), normalized to Lamin A/C levels. The degradation curves
lus sirtinol plus MG132 (green). Data shown are mean ± SEM. *p < 0.05.
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Figure 2. SIRT2 Regulates Slug Protein
Abundance and Activity
(A) (Left) Immunoblots showing levels of Slug, V5-
tagged SIRT2 (SIRT2-V5), and Lamin A/C in
MCF10A cells ectopically expressing SIRT2-V5
or control lacZ. (Right) Quantification of relative
Slug levels from five independent experiments,
normalized to Lamin A/C. Data are shown as
mean ± SEM. *p < 0.05.
(B) (Left) Immunoblots showing levels of Slug,
SIRT2, acetylated tubulin (a bona fide SIRT2 sub-
strate), and Lamin A/C inMCF10A cells expressing
two different hairpins targeting SIRT2. (Right)
Quantification of relative Slug levels from three
independent experiments, normalized to Lamin
A/C. Data are shown as mean ± SEM. **p < 0.01.
(C) (Top) Immunoblots showing levels of Slug,
SIRT2-V5, Cyclin D1, and Lamin A/C in CHX-
treatedMCF10A cells overexpressing SIRT2-V5 or
control LacZ. (Bottom) Quantification of relative
Slug levels from three independent experiments,
normalized to Lamin A/C. Data are shown as
mean ± SEM. *p < 0.05.
(D) (Top) Immunoblot showing levels of Slug,
SIRT2-V5, and Lamin A/C in CHX-treatedMCF10A
cells expressing either shSIRT2 or a non-silencing
shRNA control (shCtrl). (Bottom) Quantification
of relative Slug levels from three independent
experiments, normalized to Lamin A/C. Data are
shown as mean ± SEM. *p < 0.05.
(E) Expression of Slug target genes EPCAM and
CDH1 in MCF10A cells overexpressing SIRT2 or
LacZ (n = 3) as determined by qRT-PCR. Data are
shown as mean ± SEM. *p < 0.05.
(F) Expression of Slug target genes EPCAM and
CDH1 in MCF10A cells expressing shSIRT2 or
shCtrl (n = 3) as determined by qRT-PCR. Data are
shown as mean ± SEM. **p < 0.01.(Figure 2A, *p < 0.05), without an observable change in SNAI2
mRNA levels (Figure S2D, *p = 0.03). Conversely, knockdown
of SIRT2 by two independent short hairpin RNAi constructs
(shRNAs) led to significantly diminished Slug protein levels (Fig-
ure 2B, **p < 0.01), without significant decrease in SNAI2mRNA
levels (Figure S2E).
We next examined whether SIRT2 regulates Slug protein
turnover. MCF10A cells overexpressing SIRT2 exhibited pro-
longed Slug stability, with high protein levels up to 4 hr following
CHX treatment (Figure 2C, *p < 0.05). By contrast, Slug pro-
tein abundance was rapidly reduced and became minimally
detectable after 4 hr in control LacZ-expressing MCF10A cellsCell Repo(Figure 2C). In addition, SIRT2 knock-
down promoted rapid destabilization of
Slug, such that Slug protein promptly dis-
appeared by 1 hr post-CHX treatment
(Figure 2D, *p < 0.05). We observed that
the half-life of Slug was prolonged from
80 to 240 min in SIRT2-overexpressing
MCF10A cells, and shortened to 40 min
in SIRT2-depleted MCF10A cells (Figures
2C and 2D). Importantly, the differencesin Slug stability were specific to genetic manipulation of SIRT2
levels, and not due to a general effect on protein degradation
because cyclin D1 was still degraded normally (Figure 2C).
To determine whether Slug repressor activity is affected by the
changes in Slug protein levels mediated by SIRT2, we examined
the expression of Slug target genes following SIRT2 perturba-
tion. Elevated Slug protein caused by SIRT2 overexpression
corresponded to stronger repression of the Slug transcriptional
targets, EPCAM and CDH1 (Figure 2E, *p < 0.05). Likewise, in
SIRT2-knockdown cells where Slug protein levels were dimin-
ished, de-repression of these Slug target genes was observed
(Figure 2F, **p < 0.01). Thus, the ability of SIRT2 to regulaterts 17, 1302–1317, October 25, 2016 1305
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Figure 3. SIRT2 Binds to and Deacetylates Slug
(A) (Top) Lysates from HEK293T cells transfected with Flag-tagged Slug (Slug-Flag) and V5-tagged SIRT2 (SIRT2-V5) were subjected to anti-Flag immuno-
precipitation. Immunoblots of Flag-Slug and SIRT2-V5 are shown. (Bottom) Lysates from MCF10A were subjected to anti-Slug immunoprecipitation (left) and
anti-SIRT2 immunoprecipitation (right). Immunoblots of endogenous Slug and SIRT2 are shown.
(B) Immunofluorescence of Slug (red) and SIRT2 (green) in MCF10A cells. DAPI (blue) was used to visualize nuclei.
(legend continued on next page)
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Slug abundance directly influences the bioavailability of Slug
protein and the expression of its downstream transcriptional
targets. Taken together, these data demonstrate that SIRT2
regulates Slug protein abundance, stability, and function.
SIRT2 Interacts with and Deacetylates Slug
Because experimental manipulation of SIRT2 expression levels
alters Slug protein stability, we next sought to determine
whether Slug might directly interact with and be a substrate of
SIRT2. Accordingly, reciprocal co-immunoprecipitation (coIP)
was performed in HEK293T cells that ectopically expressed
Flag-tagged Slug and V5-tagged SIRT2. Indeed, Slug co-immu-
nopurified with SIRT2 (Figure 3A). Likewise, reciprocal coIPs
between endogenous SIRT2 and endogenous Slug in MCF10A
were also observed (Figure 3A). We further ruled out the possibil-
ity of non-specific interaction between SIRT2 and Slug mediated
through chromatin by performing the coIP in the presence of
DNase (Figures S3A and S3B). Notably, Slug failed to co-immu-
noprecipitate with SIRT1, indicating a specific interaction with
SIRT2 (Figure S2C). Consistent with these findings, dual-immu-
nofluorescence (IF) staining of endogenous Slug and SIRT2
proteins revealed their nuclear co-localization in MCF10A cells
(Figure 3B). Together, these results show that SIRT2 physically
interacts with Slug protein, suggesting that Slug may be a sub-
strate for the enzymatic activity of the deacetylase SIRT2.
SIRT2, like other members of the mammalian sirtuin family,
regulates its substrate proteins by directly modulating their acet-
ylation state. Given our finding that acetylation targets Slug
protein for degradation (Figure 1), we asked whether SIRT2 con-
stitutes an integral component of this regulatory mechanism. To
determine whether SIRT2 deacetylates Slug, we first examined
Slug acetylation status following SIRT2 inhibition by sirtinol.
This treatment resulted in the hyper-acetylation of Slug relative
to untreated cells (Figure 3C). Similarly, SIRT2 depletion using
two independent shRNAs promoted acetylation of Slug protein
(Figure S4B). By contrast, when we overexpressed SIRT2 in un-
treated cells, a marked decrease in Slug acetylation was evident
(Figure 3C, p < 0.01). However, treatment of SIRT2-overexpress-
ing cells with sirtinol restored the hyper-acetylated status of
Slug (Figure 3C, p < 0.01). Because protein acetylation and
ubiquitination are often linked and act in concert to influence pro-
tein degradation (Jiang et al., 2011; Wang et al., 2012), we next
examined whether de-acetylation of Slug by SIRT2 could
affect Slug ubiquitination and degradation. Indeed, SIRT2 over-
expression markedly reduced Slug ubiquitination (Figure S3C).
Conversely, enzymatic inhibition of SIRT2 by sirtinol treatment
promoted Slug ubiquitination (Figure S3C).
To specifically determine whether the deacetylase activity
of SIRT2 is necessary for regulating Slug protein levels, we
created single amino acid substitutions within the catalytic(C) (Left) Anti-Flag immunoprecipitation of lysates fromHEK293T cells, overexpres
were immunoblotted for pan-acetylated lysine, Flag-Slug, and SIRT2-V5. (Right)
normalized to immunoprecipitated Flag-Slug. Data are shown as mean ± SEM. *
(D) (Left) Immunoblots showing levels of Slug, Cyclin D1, and Lamin A/C in CHX-tre
SIRT2 mutants H187Y (top) and S368D (bottom). (Right) The degradation curves
Lamin A/C and plotted for cells overexpressing LacZ (black), WT SIRT2 (blue), or S
mean ± SEM. *p < 0.05.domain of SIRT2 to produce deacetylase-defective mutants
(North and Verdin, 2007; North et al., 2003). In cells overexpress-
ing these mutant proteins, Slug acetylation was significantly
higher than in cells overexpressing wild-type (WT) SIRT2 (Fig-
ure S3D). Importantly, overexpression of the deacetylase-
defective SIRT2 H187Y and S368D mutants failed to stabilize
Slug (Figure 3D, *p < 0.05). Consistently, overexpression of WT
SIRT2, but not the deacetylation-defective mutants, resulted in
increased Slug abundance at the steady state (Figure S3E).
Furthermore, the SIRT2 mutants failed to appreciably alter Slug
target gene expression (Figure S3F). Collectively, these data
show that SIRT2 deacetylase activity can alter the acetylation
state of Slug and coordinate its ubiquitination, thereby control-
ling Slug stability and activity.
Identification of K116 as an Acetylated Slug Substrate
of SIRT2
To further validate our findings, we searched for acetylated
residues of Slug by immunoprecipitating and subjecting Slug
protein to proteolytic digestion and liquid chromatography-
tandem mass spectrometry analysis (LC-MS/MS) (Figures 4A
and S4A). Using this approach, we identified acetylated residues
at K8, K116, and K166 in the SNAG, SLUG, and zinc finger
domains, respectively (Figures 4A–4C). Sequence alignment re-
vealed that all three acetylation sites are highly conserved across
species (Figure 4B).
By virtue of their locations in the regulatory SNAG and func-
tionally unknown SLUG domains, we decided to focus our
investigation on whether K8 or K116 are substrates of SIRT2.
We deemed that K166, found in the zinc finger domain that func-
tions in DNA binding, would be unlikely to affect Slug protein
degradation. To investigate whether K8 or K116 are substrates
of SIRT2, we constructed acetyl-lysine mimic (KQ) Slug mutants
at these sites and assessed their impact on Slug stability medi-
ated by SIRT2 in MCF10A cells. SIRT2 overexpression stabilized
the K8Q Slug mutant in a similar fashion to WT Slug (Figure 4D,
*p < 0.05), suggesting that K8 acetylation is not required for the
SIRT2-dependent regulation of Slug. In contrast, SIRT2 overex-
pression failed to stabilize the K116Q Slug mutant (Figure 4E,
*p < 0.05). Furthermore, SIRT2 knockdown failed to destabilize
a non-acetyl-lysine mimic (K116R) Slug mutant (Figure S4C,
*p < 0.05). Together, these data suggest that the K116 residue
in the SLUG domain represents a critical deacetylation target
required for mediating SIRT2-driven Slug stabilization.
To further corroborate this finding, we studied the direct
effect of reversible acetylation at K116 on Slug protein sta-
bility using acetyl-lysine mimic (K116Q) and non-acetyl-lysine
mimic (K116R) Slug mutants, without altering WT SIRT2
levels. Compared to WT Slug, the acetylation-mimic K116Q
mutant was rapidly degraded, whereas the degradation of thesing Slug-Flag and/or SIRT2-V5 that were treatedwith sirtinol or vehicle control
Relative levels of acetylated Slug protein from three independent experiments,
*p < 0.01.
atedMCF10A cells expressing control LacZ,WT SIRT2, or catalytically inactive
of relative Slug protein from three independent experiments are normalized to
IRT2mutants H187Y and S368D (red and green, respectively). Data shown are
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acetylation-resistant K116R mutant was attenuated in MCF10A
cells (Figure 4F, *p < 0.05). Thus, the mutational analysis of the
K116 residue of Slug partially phenocopies the Slug stability re-
sults generated using acetylation inhibitors and the genetic
manipulation of SIRT2. Taken together, these results suggest
that reversible acetylation of K116 is sufficient to regulate Slug
proteolytic turnover, and further elucidate the mechanistic
framework of how SIRT2 regulates Slug.
SIRT2 Is Highly Amplified andExpressed in HumanBLBC
Given our discovery that SIRT2 is an essential regulator of
Slug homeostasis in the normal breast epithelium, we evalu-
ated the relevance of this regulation to human breast cancer.
Clinically, breast tumors are commonly classified into distinct
subtypes based on their intrinsic molecular or histological fea-
tures. Slug protein overabundance is frequently observed in
the BLBC molecular subtype, which histologically exhibits basal
differentiation with infiltrating ductal features and is predomi-
nantly associatedwith triple-negative tumors (estrogen receptor,
progesterone receptor, andHER2 negative) (Foulkes et al., 2010;
Proia et al., 2011; Rakha et al., 2008; Storci et al., 2008). We
therefore assessed whether SIRT2 expression is altered in spe-
cific breast cancer subtypes.
Analyzing The Cancer Genome Atlas (TCGA) dataset, we first
examined SIRT2 somatic copy number status and gene expres-
sion in tumor samples from nearly 1,000 breast cancer cases
(Cerami et al., 2012). Molecular subtype classification revealed
that SIRT2 is frequently amplified in BLBCs (23%) compared to
luminal A and luminal B tumors (9% and 16%, respectively) (Fig-
ure 5A, ****p < 0.001). In addition, SIRT2 mRNA was markedly
elevated in basal-like tumors when compared to other subtypes
of breast cancer (Figure 5B, ****p < 0.001).
To corroborate to these findings, we examined SIRT2 protein
levels in 192 breast cancer cases by immunohistochemistry
(IHC). Patient stratification based on receptor status revealed
that SIRT2 levels were higher in triple-negative breast cancer
cases, when compared to the non-triple-negative breast cancer
cases (estrogen receptor-, progesterone receptor-, and/or
HER2-positive tumors) (Figures 5C and 5D, ****p < 0.001). Inter-
estingly, among the triple-negative cohort, further stratification
based on histological subtypes revealed a striking difference inFigure 4. Identification of K116 as an Acetylated Slug Substrate of SIR
(A) Anti-FLAG immunoprecipitation of HEK293T cells overexpressing FLAG-Slug,
digested and analyzed by mass spectrometry.
(B) Schematic summarizes the three identified acetylated residues in relationship t
acetylated residues are highly conserved across different species.
(C) LC-MS/MS spectrums are displayed for each of the three acetylated Slug re
(D) (Top) Immunoblots comparing the effect of SIRT2 overexpression on WT Slug
SIRT2-V5 is included to show SIRT2 overexpression. (Bottom) The degradati
normalized to Lamin A/C and plotted for cells overexpressing WT Slug plus LacZ
(red). Data shown are mean ± SEM. *p < 0.05.
(E) (Top) Immunoblots comparing the effect of SIRT2 overexpression in WT vers
V5-SIRT2 is included to show SIRT2 overexpression. (Bottom) The degradati
normalized to Lamin A/C and plotted for cells overexpressing WT Slug plus LacZ
(red). Data shown are mean ± SEM. *p < 0.05.
(F) (Left) Immunoblots showing the stability of the acetylation-mimic K116QSlugm
The degradation curves of relative Slug protein from three independent experime
(blue), K116R Slug mutant (green), and K116Q Slug mutant (red). Data shown arSIRT2 protein level among invasive lobular carcinoma (ILC)
and invasive ductal carcinoma (IDC) (Figures 5E and 5F, ****p <
0.001). SIRT2 protein was abundantly expressed in triple-nega-
tive tumors with IDC features, a poorly differentiated histological
subtype most commonly associated with highly expressed Slug
(Martin et al., 2005; Prasad et al., 2009). In contrast, triple-nega-
tive tumors with ILC features showed lower SIRT2 protein
expression, at levels comparable to non-triple-negative tumors
(Figures 5E and 5F). Consistent with the SIRT2 protein level re-
sults, further analysis of TCGA data revealed that SIRT2 copy
number amplification most frequently occurs in IDC, especially
in the basal subtypes (49%) (Figure 5G, p = 0.001). Furthermore,
SIRT2 gene expression is overall highly expressed in IDC
compared to ILC (Figure 5H, ****p < 0.001).
SIRT2 Is Necessary for Slug Overabundance
in BLBC Cells
Considering the frequent overexpression of SIRT2 in invasive
ductal BLBCs, we asked whether inhibiting SIRT2 would cause
Slug protein levels to diminish in BLBC cell lines. For these ex-
periments, we identified two BLBC cancer cells (SUM149 and
SUM1315) derived from IDCs that exhibit robust Slug expression
and stability (Proia et al., 2011). Indeed, targeting SIRT2 by two
independent shRNAs greatly diminished Slug protein levels in
both cell lines (Figures 6A and 6B).
Notably, the half-lives of Slug in these BLBC cells are longer
than those in normal epithelial cells (Proia et al., 2011) (Figures
1A, 6E, and 6F); we therefore investigated whether SIRT2 is
necessary for the aberrant stabilization of Slug protein using
these BLBC cells. SIRT2 knockdown caused rapid degradation
of Slug protein, effectively abolishing extended Slug stability
(Figures 6C and 6E). Similarly, pharmacological inhibition of
SIRT2 also led to higher degradation rates for Slug, resembling
the normal Slug turnover kinetics in MCF10A cells (Figures 1A,
6D, and 6F). Collectively, these results demonstrate that SIRT2
is necessary for Slug overabundance in BLBC.
Silencing SIRT2 Causes the Loss of Aggressive BLBC
Features and Inhibits Tumor Growth
Through regulation of transcriptional programs that orchestrate
basal differentiation, stem cell activity, cellular motility, andT2
followed by pan-acetylated lysine blotting detects acetylated Slug, which was
o functional domains of Slug. Sequence alignment analysis shows that all three
sidues.
versus an acetylation-mimic K8Q Slug mutant in MCF10A cells. Immunoblot of
on curves of relative Slug protein from three independent experiments are
control (blue), WT Slug plus SIRT2 (green), and K8Q Slug mutant plus SIRT2
us an acetylation-mimic K116Q Slug mutant in MCF10A cells. Immunoblot of
on curves of relative Slug protein from three independent experiments are
control (blue), WT Slug plus SIRT2 (green), and K116Q Slug mutant plus SIRT2
utant and the acetylation-resistant K116R Slugmutant inMCF10A cells. (Right)
nts are normalized to Lamin A/C and plotted for cells overexpressing WT Slug
e mean ± SEM. *p < 0.05.
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Figure 5. SIRT2 Expression Is Elevated in BLBCs
(A) SIRT2 somatic copy number analysis by TCGA across the molecular subtypes of breast cancer. Data were analyzed using two-tailed unpaired
Student’s t tests, p values for basal versus luminal A = 0.011, basal versus luminal B = 0.031, basal versus Luminal A/B = 0.488, basal versus HER2+ =
0.040.
(B) SIRT2 gene expression across the molecular subtypes of breast cancer from the TCGA dataset. Data were analyzed using one-way ANOVA. Data shown are
mean ± SEM. ****p < 0.0001.
(C) Immunohistochemical analysis of SIRT2 protein expression in tissue microarrays containing 192 breast tumor samples. Shown is the comparison of
SIRT2 expression between triple-negative and non-triple-negative breast cancer cases. Data were analyzed using two-tailed unpaired Student’s t test.
****p < 0.0001.
(D) Representative SIRT2 immunohistochemical staining from triple-negative and non-triple-negative breast cancer cases are shown.
(E) Triple-negative (TN) cases were further stratified by histological classification, and shown is the comparison of SIRT2 expression between TN-ILC and TN-IDC.
Data were analyzed using two-tailed unpaired Student’s t test. ****p < 0.0001.
(F) Representative SIRT2 immunohistochemical staining from TN-invasive lobular carcinoma and TN-IDC are shown.
(legend continued on next page)
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invasiveness, Slug enables aggressive malignant characteris-
tics manifested by BLBCs (Kao et al., 2014; Phillips et al.,
2014; Proia et al., 2011; Samanta et al., 2016). We hypothe-
sized that SIRT2 may also regulate the BLBC phenotype
through its effect on Slug. Given the importance of high Slug
expression as a determinant of basal differentiation status (Phil-
lips et al., 2014; Proia et al., 2011; Storci et al., 2008), we first
examined whether perturbation of SIRT2 might alter the differ-
entiation status of BLBC. Following SIRT2 depletion in the
BLBC cell lines SUM149 and SUM1315, we interrogated the
expression levels of luminal and basal differentiation genes.
Increased expression of several luminal differentiation markers,
including GATA3, KRT18, and CD24 were observed upon
SIRT2 inhibition, and concomitant repression of basal- and
stem cell-associated markers was also apparent (Figure 7A,
*p < 0.05).
The predilection to early metastasis is a key aspect of the poor
prognosis in BLBC (Anders and Carey, 2009; Kennecke et al.,
2010). Slug is a well-recognized inducer of the EMT, enabling
the dissemination and invasion of cancer cells (Bolo´s et al.,
2003; DiMeo et al., 2009; Kim et al., 2014; Taube et al.,
2010). We therefore examined whether SIRT2 perturbation
alters the invasive phenotypes of BLBC. Matrigel invasion as-
says were performed using SUM149 and SUM1315 cells that
were depleted of SIRT2. SIRT2-depleted cells exhibited signifi-
cantly reduced invasive capabilities (Figure 7B, ***p < 0.001),
correlating with the diminished Slug protein levels in these cells
(Figure 6). Importantly, the dampening of invasion in SIRT2-
depleted cells can be rescued by overexpressing WT Slug or
its non-acetyl-lysine K116R variant (Figures S5A and S5B).
Surprisingly, we observed that overexpression of the acetyl-
lysine mimic K116Q variant also rescues invasion (Figures S5A
and S5B), but one caveat is that driving overexpression of the
K116Q variant may outweigh its decrease in stability. At the
molecular level, the reduction in invasion in SIRT2-deficient cells
was accompanied by an upregulation of E-Cadherin and down-
regulation of Vimentin, two Slug targets that are canonical EMT
markers associated with cancer metastasis (Figures S5C and
S5D) (Hajra et al., 2002; Thiery, 2002). Indeed, high SIRT2
expression clinically correlates with metastatic recurrence (van
de Vijver et al., 2002) (Figure S5E, *p < 0.05).
Another essential feature underlying the aggressiveness of
BLBC is robust self-renewal and tumor-initiating capability,
contributing to therapeutic resistance and early recurrence (Fill-
more and Kuperwasser, 2008; Foulkes et al., 2010; Metzger-
Filho et al., 2012; Rakha et al., 2008). Because Slug is a major
regulator of the stem cell state and contributes to the genesis
and progression of BLBC, we examined whether the loss of
SIRT2 might affect Slug-associated, stem-like features in
BLBC (Guo et al., 2012; Proia et al., 2011; Samanta et al.,
2016). Indeed, SIRT2 silencing in SUM1315 and SUM149 cells
markedly inhibited their ability to form tumor spheres in suspen-
sion, a phenotypic assay commonly employed to assess the(G) SIRT2 somatic copy number analysis by TCGA in ILC and IDC subclasses. Da
versus IDC (basal) = 0.001, ILC versus IDC (luminal A) = 0.001, ILC versus IDC (l
(H) SIRT2 gene expression from the TCGA dataset for the ILC and IDC subclass
****p < 0.0001.self-renewal and tumor-initiating characteristics of cancer cells
(Ponti et al., 2005) (Figure 7C, ***p < 0.001).
We have previously shown thatSNAI2/Slug knockout mice are
highly resistant to mammary tumorigenesis (Cobaleda et al.,
2007; Guo et al., 2012; Nassour et al., 2012; Phillips et al.,
2014). Given our finding that SIRT2 depletion and the conse-
quent abrogation of Slug stabilization causes the loss of tumor
sphere-forming capability of BLBC cells, we addressed the
in vivo relevance of SIRT2 inhibition in BLBC by examining
tumorigenesis. SIRT2-depleted BLBC cancer cells (SUM149)
were orthotopically implanted into the mammary fat pad of fe-
male NOD/SCID mice, and tumor growth was monitored over a
16-week time span. Over this period, SIRT2 inhibition signifi-
cantly impaired the growth of tumor xenografts (Figure 7D,
***p < 0.001). In aggregate, these data demonstrate that SIRT2
inhibition dampens the cancer-associated activities mediated
by Slug in BLBC.
DISCUSSION
Slug/SNAI2 is a labile protein that is strictly regulated in normal
tissues; however, disruption of this regulation appears to be a
widespread phenomenon in human epithelial malignancies and
manifests as Slug overabundance in BLBC. In this study, we
identified acetylation as a regulatory mechanism that governs
Slug stability in human mammary epithelial cells. We elucidated
the role of SIRT2 as a major regulator of Slug stability via its abil-
ity to deacetylate the K116 residue of the SLUG domain.
Together with frequent SIRT2 overexpression in human BLBC,
our findings describe a molecular pathway that contributes to
the abnormal Slug stabilization frequently observed in this
aggressive subtype of breast cancer and therefore may provide
a rational therapeutic avenue for targeting BLBC tumors.
Our study has shown that Slug is acetylated and that post-
translational acetylation of Slug acts to promote degradation
and thereby limit Slug abundance. Although the paralogous
protein Snail has been shown to be acetylated in the zinc finger
region to limit its transcriptional activity (Hsu et al., 2014), acety-
lation has not been reported for Slug. Interestingly, our muta-
tional analysis pinpointed the K116 residue of the SLUG domain,
a region not shared with Snail, as the principle regulatory site for
Slug stability and SIRT2-mediated deacetylation. Thus, our re-
sults elucidate an important functionality of the SLUG domain.
Accordingly, we speculate that other factors such as acetyl-
transferases might also be involved in, and cooperate with,
SIRT2 to regulate Slug protein stability. Collectively, these data
expand upon the known regulatory repertoire by which phos-
phorylation and ubiquitination coordinately regulate Slug protein
stability (Wu et al., 2012; Kao et al., 2014), raising intriguing ques-
tions regarding the complex interplay among these PTMs and
how they collectively regulate Slug protein abundance. For
example, do acetylation and multiple PTMs operate in a serial
or parallel fashion? Is the interaction between acetylation andta were analyzed using two-tailed unpaired Student’s t tests; p values for: ILC
uminal B) = 2.72 3 106, ILC versus IDC (HER2+) = 0.001.
es. Data were analyzed using one-way ANOVA. Data shown are mean ± SEM.
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Figure 6. SIRT2 Is Required for Slug Stability in BLBCs
(A) Immunoblots showing the effect of SIRT2 knockdown on Slug protein abundance in SUM149 BLBC cells, compared to a non-targeting hairpin control (shCtrl).
Acetylated-tubulin levels are also shown to assess SIRT2 deacetylation activity.
(B) Immunoblots showing the effect of SIRT2 knockdown on Slug protein abundance in SUM1315 BLBC cells, compared to a non-targeting hairpin control
(shCtrl). Acetylated-tubulin levels are also shown to assess SIRT2 deacetylation activity.
(C) (Top) Immunoblots showing Slug degradation in SIRT2-depleted SUM149 cells, compared to a non-targeting hairpin control (shCtrl). (Bottom) Immunoblots
showing the effect of SIRT2 inhibition by sirtinol on Slug degradation in SUM149 cells, compared to DMSO vehicle treatment.
(D) Quantification from three separate experiments shows the effect of genetic silencing or pharmacological inhibition of SIRT2 in SUM149 cells. Data shown are
mean ± SEM. *p < 0.05.
(E) (Top) Immunoblots showing Slug degradation in SIRT2-depleted SUM1315 cells, compared to a non-targeting hairpin control (shCtrl). (Bottom) Immunoblots
showing the effect of SIRT2 inhibition by sirtinol on Slug degradation in SUM1315 cells, compared to DMSO vehicle treatment.
(F) Quantification from three separate experiments shows the effect of genetic silencing or pharmacological inhibition of SIRT2 in SUM1315 cells. Data shown are
mean ± SEM. *p < 0.05.other PTMs cooperative or antagonistic in nature? Previouswork
has shown that acetylation can promote E3 ligase-mediated
ubiquitination inmultiple proteins subject to rapid turnover (Jiang
et al., 2011; Liu et al., 2013a; Wang et al., 2012). In some con-
texts, acetylation also regulates subcellular localization to facili-
tate proteasomal degradation of the target protein (Fujita et al.,1312 Cell Reports 17, 1302–1317, October 25, 20162015; Song et al., 2015). Future studies are needed to fully
understand how acetylation is integrated into the regulatory
network regulating Slug abundance and its downstream biolog-
ical effects.
The transcriptional repressor Slug/SNAI2 is frequently deregu-
lated in tumor cells, resulting in extended Slug stability. Although
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Figure 7. Silencing SIRT2 Causes the Loss of Aggressive BLBC Features in Cancer Cells
(A) qRT-PCR analysis of expression levels of Slug target genes as well as luminal and basal differentiation markers following SIRT2 silencing in SUM149 (red) and
SUM1315 (blue) BLBCs. Genes differentially expressed are represented as a log2 fold change over the non-targeting shCtrl cell lines. Data shown are mean ±
SEM. *p < 0.05.
(B) (Left) Representative images showing the effect ofSIRT2 silencing on the invasive capacity of SUM149 and SUM1315 cancer cells, compared to non-targeting
hairpin control (shCtrl). (Right) The total number of cells invading through the Matrigel-coated transwell were quantified (n = 3 per cell line). Data are shown as
mean ± SEM. ***p < 0.001.
(C) Tumor sphere-forming ability of SUM149 and SUM1315 cells following SIRT2 depletion, compared to a non-targeting hairpin control (shCtrl). Quantification is
from three independent experiments. Data are shown as mean ± SEM. ***p < 0.001.
(D) Quantification of tumor mass (left panel) and photograph (right panel) of SUM149 cells grown as orthotopic xenografts in NOD/SCID mice. Tumors with two
different hairpins targeting SIRT2 or a non-targeting hairpin control (shCtrl) are indicated. Data are plotted as individual data points from the five animals of each
group. The mean ± SEM are shown, and comparisons between groups were performed using two-tailed Student’s t tests. ***p < 0.001.this ultimately drives transcriptional programs that confer tumor-
initiating and invasive capabilities, resistance to apoptosis, and
therapeutic failure (Chang et al., 2011; Guo et al., 2012; Kurrey
et al., 2009; Wang et al., 2009; Wu et al., 2005), the molecular
basis of Slug protein stabilization in cancer has remained
unclear. Here, we have elucidated a mechanism by which theprotein deacetylase SIRT2 acts as a critical mediator of Slug
protein stability. Although the oncogenic role of SIRT2 remains
controversial and earlier evidence showed that SIRT2 loss mildly
predisposed aged animals to mammary tumors (Kim et al.,
2014), SIRT2 is highly expressed in multiple types of human can-
cer, and inhibition of SIRT2 generally exhibits anti-cancer effectsCell Reports 17, 1302–1317, October 25, 2016 1313
(Zhang et al., 2009; Rotili et al., 2012; McCarthy et al., 2013;
Hoffmann et al., 2014; Heltweg et al., 2006; Chen et al., 2013;
Dan et al., 2012; Grbesa et al., 2015; Singh et al., 2015). Our
data support this latter evidence, as we have found that SIRT2
is frequently overexpressed in the aggressive basal subtype of
breast cancer, which is most strongly associated with the phe-
nomenon of Slug overabundance. Notably, when we destabi-
lized Slug by genetic depletion or pharmacological inhibition of
SIRT2 in Slug-stabilizing BLBC cells, the cancer cells lost key
aspects of BLBC character, including basal differentiation genes
expression, tumor sphere-forming ability, and invasion. Collec-
tively, these data connect the basic mechanistic regulation of
Slug by SIRT2 to the context of Slug overabundance in BLBC tu-
mors. Furthermore, in line with the emerging role of sirtuins in the
proteolytic turnover of labile proteins (Jiang et al., 2011; Liu et al.,
2013a; Wang et al., 2012), co-opting this molecular mechanism
to aberrantly stabilize cancer drivers could be a general feature
of cancer cells for adopting malignant behaviors.
From a therapeutic standpoint, our work presents important
insights into molecular strategies to dampen Slug stabilization
in BLBC. We provide evidence that SIRT2 inhibition accelerates
proteasomal degradation of Slug, even in BLBC cells that exhibit
extended Slug stability (Proia et al., 2011). Importantly, SIRT2
inhibition in these BLBC cells caused the loss of the basal
differentiation gene expressions, colony-forming ability, and
invasiveness characteristic of aggressive BLBC, ultimately re-
sulting in diminished tumorigenic capability. Interestingly, a
recent study demonstrated that selective SIRT2 inhibition has
broad anti-cancer effects, in part by promoting the proteasomal
degradation of the c-Myc oncoprotein (Jing et al., 2016).
Notably, in this study, several BLBC cancer cells also exhibited
sensitivity to SIRT2 inhibition despite no observable decrease
of c-Myc, suggesting that destabilization of other cancer-rele-
vant substrates of SIRT2, such as Slug, may contribute to this
anti-cancer effect in BLBCs. Taken together with our findings,
the pharmacological inhibition of SIRT2 may owe its remarkable
anti-cancer property in BLBCs to its potent effect on essential
tumorigenic substrates such as Slug and c-Myc. Overall, these
findings motivate future preclinical studies to more rigorously
address the in vivo efficacy of SIRT2 inhibition against BLBC
formation and progression. Because SIRT2 regulates a number
of protein substrates involved in diverse biological processes
(Black et al., 2008; Liu et al., 2013a; North et al., 2003; Zhang
et al., 2016; Zhao et al., 2014), an alternative targeting strategy
such as peptide inhibitors that selectively block SIRT2 and
Slug interaction may be more useful for these purposes. This
rational approach, if successful, would significantly reshape
our abilities to combat BLBC and improve the associated poor
disease prospects.
EXPERIMENTAL PROCEDURES
Cell Lines, Tissue Cultures, and Chemical Treatments
Cell lines used in this study were purchased from ATCC (MCF10A and
HEK293T) or obtained from Dr. Stephen Ethier (SUM149 and SUM1315).
Additional tissue culture details are provided in Supplemental Experimental
Procedures. For analysis of protein stability, cells were treated with the protein
synthesis inhibitor CHX (4 mg/ml; Sigma-Aldrich) followed by pulse-chase at
indicated time points. Deacetylation inhibitors sodium butyrate (10 mM;1314 Cell Reports 17, 1302–1317, October 25, 2016Sigma-Aldrich), nicotinamide (5 mM; Sigma-Aldrich), trichostatin A (10 mM;
Sigma-Aldrich), sirtinol (12.5 mM; Sigma-Aldrich), deacetylation inhibitor
cocktail (Santa Cruz), and Nedd8-activating enzyme inhibitor MLN4924
(10 mM; Calbiochem) were added to cells 6 hr before harvest.
Cell Transfections, Immunoblotting, and Immunoprecipitation
Full-length SIRT1, SIRT2, and SNAI2 were cloned into plenti6.2-V5/DEST
destination vector or pPGS-Flag vector. Point mutations for SIRT2 and Slug
were generated by site-directed mutagenesis. Plasmid transfections were
carried out using Fugene HD (Promega) according to the manufacturer’s pro-
tocol. To isolate protein from whole-cell lysis for immunoblotting, cells were
lysed in RIPA buffer (10 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.1% SDS) sup-
plemented with protease inhibitor cocktail (Roche). For immunoprecipitation
experiments, whole-cell protein lysates were pre-cleared by incubating with
either Dynabeads (Life Technologies) or FLAG-M2 agarose beads (Sigma-
Aldrich) for 1 hr, and then incubated with antibodies overnight. Complexes
were then bound to beads for 2 hr, washed three times with lysis buffer, and
eluted by boiling in SDS loading buffer. Protein samples were separated by
SDS-PAGE according to standard procedures, transferred onto a nitrocellu-
lose membrane, and blocked with 5% milk. Immunoblotting was performed
according to standard procedures, and membranes were developed with
either West Pico or West Dura ECL substrate (Pierce).
Acetylation Assay and Mass Spectrometry Analysis
Cultured cells were treated with 10 mM MG132 proteasome inhibitor (Sigma-
Aldrich) and 1:100 dilution of deacetylation inhibitor cocktail (Santa Cruz) for
4 hr before harvest, and then cells were lysed and washed in RIPA buffer
supplementedwith protease inhibitor cocktail (Roche), MG132 proteasome in-
hibitor, and deacetylation inhibitor cocktail. Flag-Slug or endogenous Slug
immunoprecipitation was performed and analyzed for acetylation by anti-acet-
ylated lysine antibodies (Cell Signaling). For protein mass spectrometry, Slug
IP lysates were separated by SDS-PAGE, fixed in the gel, and stained with
Coomassie Blue. To identify acetylated residues in Slug protein, the gel slice
containing the full-length Slug protein was excised, trypsin digested, and
analyzed by liquid chromatography-tandem mass spectrometry (Taplin
Mass Spectrometry Facility, Harvard Medical School). For the identification
of Slug-binding partner proteins, the gel was partitioned into five sections for
trypsin digestion and downstream analysis.
Patient Tumor Arrays Analysis
The breast cancer tissue microarrays (TMAs) containing 192 cases of pri-
mary breast tumors with annotated receptor status were purchased from US
Biomax (BR1921 and BR487). Each specimen consisted of a 5-mm-thick
core section, which was immunostained with anti-SIRT2 antibodies (Sigma).
IHC was performed using the avidin-biotin complex method (Vector Labora-
tories). Additional IHC details are provided in Supplemental Experimental Pro-
cedures. IHC staining was analyzed in a pathologist-blinded fashion using
automated quantitative imaging method (Panoramic scanner; 3D HISTECH).
The two-tailed unpaired Student’s t test was used for statistical analysis of
SIRT2 expression between patient cohorts.
Tumor Sphere, Invasion, and Orthotopic Tumor Xenograft Assays
For tumor sphere assays, 1 3 103 cells each of SUM149 and SUM1315 were
seeded in six-well Ultra-Low Attachment Surface tissue culture plates (Corn-
ing Life Sciences) and cultured for 1 week. Floating tumor spheres were
collected and diluted in Isoton II (Beckman Coulter) and glycerol, and analyzed
using Multisizer 3 cytometer (Beckman Coulter). Invasion assays were carried
out in 24-well plate with 8-mm pre-coated Matrigel chamber inserts (Corning
Life Sciences). A total of 2 3 105 SUM cells was plated in serum-free medium
on top of the insert with SUM media containing 10% FBS at the bottom of the
insert, and cultured for 24 hr. Chamber inserts were then washed, scraped,
methanol fixed, and stained with Crystal Violet. Invaded cells were visualized
under the microscope and counted using ImageJ software (NIH). The invaded
cells were normalizedwith 24-hr cell proliferation asmeasured by the CellTiter-
Glo assay (Promega). For orthotopic tumor xenograft assays, all procedures
were performed in accordance with the animal protocol approved by the
Tufts University Institutional Animal Care and Use Committee. Prior to
surgery, 10-week-old, female NOD/SCID mice (The Jackson Laboratory) were
anesthetized by isoflurane. An incision was made along the right flank to
expose the inguinal mammary gland, and 2.0 3 106 cells in a total volume of
50 mL of 1:1 Matrigel: PBS was injected into the gland. Post-operative
analgesic and monitoring were provided. Animals were sacrificed 16 weeks
after the surgery, and tumors were dissected and weighted. All experiments
involving animal subjects were performed in accordance with the animal
protocol approved by the Tufts University Institutional Animal Care and Use
Committee. The approval number for animal research is B2016-67.
Statistical Analysis
Data were analyzed and compared between groups using two-tailed Stu-
dent’s t tests and one-way ANOVA, and p < 0.05 was considered statistically
significant.
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